Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.80 |
| ▸ | MAOA | P21397 | 9/20 | 0.80 |
| ▸ | TLR4 | O00206 | 6/20 | 0.62 |
| ▸ | TLR2 | O60603 | 6/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | FBP1 | P09467 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566004 | 1.00 | MAOB (0.80) | MAOBMAOATLR4TLR2GSK3B | |
| SCHEMBL236394 | 0.84 | MAOA (0.72) | MAOBMAOATLR4TLR2GSK3B | |
| SCHEMBL236393 | 0.84 | MAOA (0.72) | MAOBMAOATLR4TLR2GSK3B | |
| SCHEMBL4342895 | 0.80 | MAOB (0.61) | MAOBMAOANR4A2 | |
| SCHEMBL31634183 | 0.80 | MAOB (0.61) | MAOBMAOANR4A2 | |
| SCHEMBL1347334 | 0.79 | MAOB (0.76) | MAOBMAOAGSK3BBACE1NR4A2 | |
| SCHEMBL29464145 | 0.79 | MAOB (0.76) | MAOBMAOAGSK3BBACE1NR4A2 | |
| SCHEMBL509860 | 0.78 | MAOA (0.72) | MAOBMAOATLR4TLR2FBP1 | |
| SCHEMBL509861 | 0.78 | MAOA (0.72) | MAOBMAOATLR4TLR2FBP1 | |
| SCHEMBL5035057 | 0.78 | GSK3B (0.78) | MAOBGSK3BBACE1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | MAOB 4070/4885MAOA 4106/4885TLR4 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.